Cannabichromevarin (CBCV) first came to limelight in 1975 when Thailand researchers at the University of Nagasaki isolated the compound from a cannabis plant. However, not much research has been conducted on the compound since its discovery.
The concentration of CBCV in cannabis plants is much lower compared to cannabidiol (CBD) and tetrahydrocannabinol (THC). CBCV is related to cannabichromene (CBC), a compound that appears in smaller amounts than the two major ones. The chemical structure of CBCV is similar to that of CBC but much shorter. CBCV can rightly be described as a propyl cannabinoid, meaning that its molecular structure contains a propyl chain. The molecular formula for this compound is C19H26O2.
Properties of CBCV
There is not much information to give concerning the properties of CBCV due to the restrictions on marijuana research. However, there is some knowledge that may be used to predict its effect on the human body.
Because of the similarity in the molecular structures of CBC and CBCV, it is believed that they may also share similar effects. However, there may be some significant differences. Propyl cannabinoids, like CBCV, often share a similar mechanism of action with their counterparts – in this case, CBC. Yet, some exhibit unique properties that cannot be found elsewhere.
Possible Therapeutic Effects of CBCV
As earlier mentioned, not much is known about the therapeutic benefits of CBCV. However, we may make some educated guesses as to its medical potential.
CBC acts as a very potent anandamide reuptake inhibitor. Studies have also shown that it has antibiotic, antifungal, analgesic, anti-inflammatory, and antidepressant effects.
If the medical benefits of CBCV turn out to be similar to CBC, then patients may benefit from it without feeling impaired, similar to CBD. We know that CBC does not have any psychoactive effects, hence users will not feel high after taking it. However, it can relieve pain, drastically minimize inflammation, and improve upon the symptoms of depression. CBCV could make these results much stronger.
Some researchers are of the opinion that all cannabinoids in a particular strain work hand-in-hand to make the substance very potent. If this is true, then CBCV can help potentiate the therapeutic effects of other compounds.
What Conditions May Be Relieved By CBCV?
Assuming the therapeutic effects of CBCV are similar to CBC, then many patients may benefit from it without experiencing any form of intoxication. CBCV has positive effects on the following medical conditions:
- Major depression
- Chronic pain
- Crohn’s disease
- Inflammatory disorders
- Parkinson’s disease
- Epileptic seizures
- Amyolateral sclerosis
- Muscular dystrophy
One of the most interesting effects of CBCV is its ability to relieve seizures in infants and children. Scientists from the Regents of the University of California have a patent on anticonvulsive medication for infants suffering from seizures. The drug indicates that its potential components are CBCV and CBC while the major component is cannabidiol. The license does not state that CBCV has the potential to relieve seizures, rather it proves that researchers have enough facts to express interest in the possible anticonvulsant properties.
Does CBCV Have Any Side Effects?
As we have earlier stated, CBCV does not have psychoactive effects, as in the case of THC, hence its side effects may not be as pronounced as that of THC.
Side effects reported by some users include lightheadedness, drowsiness, low blood pressure, and dry mouth. Users are also advised not to drive or operate heavy machinery after using CBCV.
Liu YJ, Fan HB, Jin Y, Ren CG, Jia XE, Wang L, Chen Y, Dong M, Zhu KY, Dong ZW, Ye BX, Zhong Z, Deng M, Liu TX, Ren R. Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway. J Biol Chem. 2013; 288(19):13551–13562. [PMC free article] [PubMed]
Aso E, Juves S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. J Alzheimers Dis. 2013; 35(4):847–858. [PubMed]
Merroun I, Sanchez-Gonzalez C, Martinez R, Lopez-Chaves C, Porres JM, Aranda P, Llopis J, Galisteo M, Zarzuelo A, Errami M, Lopez-Jurado M. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats. Metabolism. 2013; 62(11):1641–50. [PubMed]
Vaseghi G, Rabbani M, Hajhashemi V. The CB (1) receptor antagonist, AM281, improves recognition loss induced by naloxone in morphine withdrawal mice. Basic Clin Pharmacol Toxicol. 2012; 111(3):161–165.